Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Neurobo Pharmaceuticals Inc (NRBO)

Neurobo Pharmaceuticals Inc (NRBO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 84,237
  • Shares Outstanding, K 22,285
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,680 K
  • 60-Month Beta 0.68
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.83
Trade NRBO with:

Options Overview Details

View History
  • Implied Volatility 161.94%
  • Historical Volatility 67.08%
  • IV Percentile 60%
  • IV Rank 42.78%
  • IV High 266.01% on 03/10/21
  • IV Low 84.14% on 05/07/21
  • Put/Call Vol Ratio 33.00
  • Today's Volume 68
  • Volume Avg (30-Day) 195
  • Put/Call OI Ratio 8.95
  • Today's Open Interest 418
  • Open Int (30-Day) 1,192

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.18
  • Number of Estimates 1
  • High Estimate -0.18
  • Low Estimate -0.18
  • Prior Year -0.19
  • Growth Rate Est. (year over year) +5.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.62 +4.42%
on 09/16/21
4.95 -23.64%
on 09/02/21
-0.17 (-4.30%)
since 08/27/21
3-Month
2.70 +40.00%
on 07/19/21
5.63 -32.86%
on 07/20/21
+0.53 (+16.31%)
since 06/25/21
52-Week
2.70 +40.00%
on 07/19/21
7.61 -50.32%
on 01/06/21
-1.97 (-34.26%)
since 09/25/20

Most Recent Stories

More News
NeuroBo Pharmaceuticals Reports Second Quarter 2021 Financial Results

/PRNewswire/ --(Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies for viral, neuropathic and neurodegenerative diseases,...

NRBO : 3.78 (-1.05%)
NeuroBo Pharmaceuticals' Shareholders Elect Hyung Heon Kim and Andrew I. Koven to NeuroBo's Board of Directors

/PRNewswire/ -- (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies for viral, neuropathic and neurodegenerative diseases,...

NRBO : 3.78 (-1.05%)
NeuroBo Pharmaceuticals Reports First Quarter 2021 Financial Results

, /PRNewswire/ --(Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies for viral, neuropathic and neurodegenerative diseases,...

NRBO : 3.78 (-1.05%)
NeuroBo Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Strategic Update

, /PRNewswire/ --(Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies for viral, neuropathic and neurodegenerative diseases,...

NRBO : 3.78 (-1.05%)
NeuroBo Pharmaceuticals Receives Approval for Amendment of Contingent Value Rights for Gemcabene

, /PRNewswire/ -- (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that it has received approval of an amendment to its Contingent Value Rights (CVR) agreement from a majority of...

NRBO : 3.78 (-1.05%)
NeuroBo Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference

, /PRNewswire/ -- (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that Company management will participate in the upcoming H.C. Wainwright Global Life Sciences Conference taking...

NRBO : 3.78 (-1.05%)
AavantiBio Adds Veteran Life Sciences Executive Douglas J. Swirsky as Chief Financial Officer and Treasurer

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Douglas J. Swirsky as Chief Financial Officer and Treasurer...

XON : 4.65 (-4.12%)
RNN : 5.24 (+0.19%)
OCUP : 5.38 (+0.94%)
CLRB : 0.9900 (+1.28%)
NRBO : 3.78 (-1.05%)
NeuroBo Pharmaceuticals Closes $10.0 Million Private Placement

, /PRNewswire/ -- (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced the closing of its previously announced private placement of an aggregate 2,500,000 shares of its common stock...

NRBO : 3.78 (-1.05%)
NeuroBo Pharmaceuticals Announces $10.0 Million Private Placement

, /PRNewswire/ --  (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors...

NRBO : 3.78 (-1.05%)
NeuroBo Pharmaceuticals Acquires ANA Therapeutics for Late-Stage Oral Antiviral Development Program

, /PRNewswire/ --(Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on it acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary...

NRBO : 3.78 (-1.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

NeuroBo Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on novel treatments for neurodegenerative diseases. The company's novel lead candidate NB-01 is a drug candidate for diabetic neuropathic pain. NB-02 focuses on the treatment of neurodegenerative diseases. NeuroBo Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 3.95
2nd Resistance Point 3.88
1st Resistance Point 3.83
Last Price 3.78
1st Support Level 3.71
2nd Support Level 3.64
3rd Support Level 3.59

See More

52-Week High 7.61
Fibonacci 61.8% 5.73
Fibonacci 50% 5.15
Fibonacci 38.2% 4.58
Last Price 3.78
52-Week Low 2.70

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar